BioPharma

Asia-Pacific’s biotechnology landscape is not just growing it is transforming. In 2026, the region stands at a unique crossroads where scientific ambition meets real-world demands. This year will test the industry’s resilience, shape global health priorities, and redefine how...

AstraZeneca has gone ahead and committed $100 million to head deeper into the KRAS space by way of securing the right when it comes to a clinical-stage, multitarget asset from Jacobio Pharma of China. The U.K.-based pharma giant has scored...

Outsourcing laboratory infrastructure to CDMOs offers pharma companies critical agility, transforming fixed capital costs into flexible operational expenses while accessing cutting-edge technology like Cryo-EM.

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Egypt has gone on to mark quite a prominent milestone when it comes to its biopharmaceutical development by laying the foundation stone for the GENNVAX vaccine manufacturing facility, which is all set to become the largest fully integrated vaccine...

Thermo Fisher Scientific has gone on to announce quite a major expansion of its Bioprocess Design Centers in Asia, hence deepening its investment within the rapidly advancing biopharmaceutical sector of the region. The company is now starting a new...

Bora Pharmaceuticals Co. Ltd., which is a global leader when it comes to pharmaceutical manufacturing, along with a leading early-phase Contract Development Manufacturing Organization – CDMO, Corealis Pharma Inc., have gone on to enter into a strategic alliance so...